DocGo price target lowered to $10 from $11 at Canaccord

Canaccord lowered the firm’s price target on DocGo to $10 from $11 and keeps a Buy rating on the shares. The firm said concerns over cash collections should ease as DocGo detailed receiving $120 million in payments so far this year and has fully paid down its line of credit. DocGo expects to commence the recent share repurchase program previously announced.